Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Ambrx, Astellas Eye Conjugate Drugs
by Michael McCoy
April 15, 2013
| A version of this story appeared in
Volume 91, Issue 15
California-based Ambrx and Japan’s Astellas Pharma are joining to discover and develop antibody-drug conjugates for oncology. Ambrx will receive an up-front payment of $15 million from Astellas and could get up to $285 million in milestone payments. Ambrx creates ADCs using site-specific conjugation technology that allows the attachment of anticancer compounds to specific points on an antibody. It also has partnerships with Bristol-Myers Squibb, Eli Lilly & Co., and other firms.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter